SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%

Canaccord Genuity Reiterates Buy on Intra-Cellular Therapies, Raises Price Target to $65

Canaccord Genuity reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $29 to $65.

Benzinga · -

Canaccord Genuity reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $29 to $65.